Regeneron Pharmaceuticals, Inc.$770.36BSX · NYSE
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $20.07B | $16.75B | $14.24B | $12.68B | $11.89B | $9.91B | $10.73B | $9.82B |
| Cost of Revenue | $6.22B | $5.26B | $4.34B | $3.96B | $3.71B | $3.46B | $3.12B | $2.81B |
| Gross Profit | $13.85B | $11.49B | $9.90B | $8.73B | $8.18B | $6.45B | $7.62B | $7.01B |
| Selling, General & Administrative | $6.89B | $5.98B | $5.19B | $4.52B | $4.36B | $3.79B | $3.94B | $3.57B |
| Operating Expenses | $10.24B | $8.89B | $7.55B | $7.08B | $6.98B | $6.53B | $6.10B | $5.50B |
| Operating Income | $3.61B | $2.60B | $2.34B | $1.65B | $1.20B | -$80.00M | $1.52B | $1.51B |
| Interest Expense | $349.00M | $305.00M | $265.00M | $470.00M | $341.00M | $361.00M | $473.00M | $241.00M |
| Other Income / (Expense) | -$228.00M | -$321.00M | -$358.00M | -$508.00M | -$123.00M | $1.00M | -$831.00M | -$85.00M |
| Income Before Taxes | $3.38B | $2.28B | $1.99B | $1.14B | $1.08B | -$79.00M | $687.00M | $1.42B |
| Provision for Income Taxes | $493.00M | $436.00M | $393.00M | $443.00M | $36.00M | $2.00M | -$4.01B | -$249.00M |
| Net Income | $2.89B | $1.85B | $1.59B | $698.00M | $1.04B | -$82.00M | $4.70B | $1.67B |
| Basic EPS | $1.96 | $1.26 | $1.08 | $0.45 | $0.69 | -$0.08 | $3.38 | $1.21 |
| Diluted EPS | $1.94 | $1.25 | $1.07 | $0.45 | $0.69 | -$0.08 | $3.33 | $1.19 |
| Basic Shares Outstanding | 1.48B | 1.47B | 1.45B | 1.43B | 1.42B | 1.42B | 1.39B | 1.38B |
| Diluted Shares Outstanding | 1.49B | 1.49B | 1.46B | 1.44B | 1.43B | 1.42B | 1.41B | 1.40B |
| Period | Consensus EPS | Low | High | Estimates | Revisions |
|---|---|---|---|---|---|
| Dec 2026 | $3.30 | $3.28 | $3.31 | 11 | ↑0 ↓11 |
| Dec 2027 | $3.42 | $3.32 | $3.71 | 12 | ↑0 ↓11 |
| Dec 2028 | $3.67 | $3.42 | $3.97 | 5 | ↑0 ↓5 |
| Dec 2029 | $3.76 | $3.53 | $3.98 | 2 | ↑0 ↓2 |
